Explain this page
Arphra AIPlain-English read on Neurocrine Biosciences, Inc.’s valuationNo recent stories.
today
- Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript14d
- Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients15d
- Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients15d
- Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities16d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $186.31 (+15.41%)
Candlestick · 1Y
Open in chart workstation →NBIX
158.29+23.49%H 169.57L 122.14MA50 147.55MA200 141.29Avg vol 1.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11% | +0.17% | +3.02% | +26.26% | +9.88% | +13.83% | +25.95% | +68.01% | +60.51% | +273.01% | +1191.52% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$164.40
Bid
$160.00
27 sh
Ask
$163.98
8 sh
Spread
$3.980
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Real Estate+1.01%
- Consumer Cyclical+0.94%
- Energy+0.84%
- Consumer Defensive+0.82%
- Financial Services+0.23%
- Basic Materials-0.11%
- Healthcare-0.18%
- Communication Services-0.18%
- Industrials-0.47%
- Technology-0.85%
- Utilities-1.03%
Top industries (issuer's industry highlighted)
- Biotechnology+3.28%
- Software - Services+9.60%
- Broadcasting+8.34%
- Travel Services+7.87%
- Computer Hardware+4.56%
- Oil & Gas Energy-3.54%
- Electrical Equipment & Parts-3.26%
- Semiconductors-2.12%
- Communication Equipment+2.06%
- REIT - Healthcare Facilities+2.01%
- Drug Manufacturers - Specialty & Generic+1.99%
- Consulting Services-1.97%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patientsprnewswire.com·Jun 08, 2026
- Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patientsprnewswire.com·Jun 08, 2026
- Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilitiesprnewswire.com·Jun 08, 2026
- Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilitiesprnewswire.com·Jun 08, 2026
- Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026gurufocus.com·Jun 03, 2026
- Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasiaprnewswire.com·May 06, 2026
Recent analyst activity
DB- Jun 02, 2026PT$213.00Goldman Sachs Resumes Neurocrine Bio. (NBIX) at BuyGoldman Sachs
Financial scores
DBJun 24, 2026Altman Z
8.39
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
5/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
No peer list available for NBIX.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|